718 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Passive Capital Management LLC.

Passive Capital Management LLC. bought a new stake in Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 718 shares of the company’s stock, valued at approximately $650,000.

Other hedge funds also recently bought and sold shares of the company. Core Wealth Advisors Inc. raised its position in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the period. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company in the second quarter valued at approximately $36,000. Frank Rimerman Advisors LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $37,000. Finally, Redmont Wealth Advisors LLC acquired a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Truist Financial restated a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Guggenheim lifted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Bank of America upped their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Finally, JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $891.01 on Thursday. The company has a market cap of $846.82 billion, a PE ratio of 131.22, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The firm has a 50-day moving average of $897.24 and a 200-day moving average of $846.22. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 52,369 shares of the stock in a transaction on Friday, July 5th. The stock was sold at an average price of $915.18, for a total value of $47,927,061.42. Following the sale, the insider now owns 97,247,403 shares in the company, valued at approximately $88,998,878,277.54. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 355,962 shares of company stock worth $331,267,535. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.